Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001140361-25-024018
Filing Date
2025-06-27
Accepted
2025-06-27 17:31:13
Documents
1
Period of Report
2025-06-26

Document Format Files

Seq Description Document Type Size
1 FORM 4 form4.html 4  
1 FORM 4 form4.xml 4 3584
  Complete submission text file 0001140361-25-024018.txt   5221
Mailing Address C/O ESPERION THERAPEUTICS, INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address
Braunstein Scott (Reporting) CIK: 0001643875 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40493 | Film No.: 251088102

Mailing Address PROF. J.H. BAVINCKLAAN 7 AMSTELVEEN Netherlands 1183
Business Address PROF. J.H. BAVINCKLAAN 7 AMSTELVEEN Netherlands 1183 49 89 2153 9035
ATAI Life Sciences N.V. (Issuer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)